The added value at Indukern, the focus on biologics at Calier and the leadership in generics and diversification at Kern Pharma continue to be key to the Group's future.
Industry news
The added value at Indukern, the focus on biologics at Calier and the leadership in generics and diversification at Kern Pharma continue to be key to the Group's future.
recently published
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.